Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
0.96
Ask:
1.10
Spread: 0.14 (14.583%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Director/PDMR Shareholding

12 Sep 2019 15:19

RNS Number : 1765M
Provexis PLC
12 September 2019
 

12 September 2019

 

Provexis plc

 

("Provexis" or the "Company")

 

Director / PDMR notification

 

 

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.

 

Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Ian Ford (Director and PDMR) - shares acquired on behalf of Mr Ford's children (under the age of 18) who are persons closely associated with Mr Ford

 

2

 

Reason for the notification

a)

 

Position/status

 

See 1a) above

 

b)

 

Initial notification

/ Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

PROVEXIS PLC

b)

 

LEI

 

21380042E3Y3N9VZ6N48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 0.1p each

 

 

 

ISIN: GB00B0923P27

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

 

 

 

 Price(s)

Volume(s)

0.33 pence

and

0.345 pence

2,500,000

 

2,500,000

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

5,000,000 shares

 

Average price of 0.338 pence per share

 

e)

 

Date of the transaction

 

12 September 2019

f)

 

Place of the transaction

 

London Stock Exchange, AIM Market

 

 

For further information please contact:

 

Provexis plc

Dawson Buck, Chairman

Ian Ford, CEO & CFO

 

Tel: 07490 391888

enquiries@provexis.com

Allenby Capital Limited

Nick Naylor / Liz Kirchner

Tel: 020 3328 5656

 

 

 

Notes for editors

 

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

 

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

 

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

 

For further information, please visit www.provexis.com and www.fruitflowplus.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGGUQGBUPBGCP
Date   Source Headline
20th May 20267:00 amRNSHolding(s) in Company
16th Apr 202612:37 pmRNSHolding(s) in Company
31st Dec 20258:22 amRNSHalf-year Financial Report
31st Dec 20258:22 amRNSHalf-year Financial Report
21st Nov 20251:38 pmRNSResult of AGM
30th Oct 20257:30 amRNSRestoration - Provexis plc
30th Oct 20257:00 amRNSFinal Results
1st Oct 20257:30 amRNSSuspension - Provexis PLC
30th Sep 20258:40 amRNSDelay in publication of annual accounts
7th Jan 20251:14 pmRNSGrant of Options and Warrants
31st Dec 20241:00 pmRNSTotal Voting Rights
31st Dec 20249:59 amRNSHalf-year Report
18th Dec 20247:00 amRNSPurchase of Fruitflow® II SD & royalty payment
25th Oct 20243:47 pmRNSResult of AGM
30th Sep 20247:00 amRNSFinal Results
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.